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Abstract. Background: Dosimetric data and acute
oesophageal toxicity (AET) during chemoradiotherapy (CRT)
were evaluated in patients with non-small cell lung cancer
(NSCLC). Patients and Methods: Fifty patients were treated
with paclitaxel-based conformal CRT with a mean±SD dose
of 60.7±9.8 Gy. The oesophageal toxicity was prospectively
registered and evaluated in relation to the maximal dose
(Dmax), mean dose (Dmean), length and volume of
oesophagus irradiated with 35-60 Gy (V35-60Gy), and
according to the seriousness of AET. Results: Dmax and
Dmean to the oesophagus were 57.0±10.8 Gy and 24.9±9.0
Gy, respectively. AET of grade 1, 2 and 3 developed in 16
(32%), 14 (28%) and three (6%) cases, respectively. The
Dmax, Dmean, length and the V35-60Gy were all related to
dysphagia (p<0.001). V45Gy was the most reliable predictor
of AET of grade 2 or more. Conclusion: Our results indicate
that keeping oesophageal V45Gy below 32.5% can prevent
severe AET during CRT of NSCLC. 
Lung cancer is the most frequent tumour worldwide.
Radiotherapy is one of the main treatment modalities for
lung cancer and had been the conventional method of
treatment until the 1980s (1). Its efficacy alone in locally
advanced non-small cell lung cancer is poor (2). Strategies
designed to enhance local control include improved tumour
targeting (three-dimensional treatment planning and
increasingly more sophisticated radiotherapy techniques),
escalation of thoracic radiotherapy dose (2-4), and
application of different fractionations (5-8). Individualized
combinations of various treatment procedures, such as
combining radiotherapy with chemotherapy tend to improve
local control and survival (9, 10). Radiosensitization has
been reported to increase therapy efficacy, but it may also
increase therapy-induced toxicity (6, 9, 11-14). The practice
of advanced techniques should reduce acute and late
treatment-associated toxicities (15, 16). Radiation
oesophagitis seems to be one of the most common acute
toxicities, especially in the setting of combined concurrent
chemoradiation (CRT) (1, 2, 17, 18). This adverse treatment
side-effect is often a dose-limiting factor (4), which
influences treatment outcomes and patients’ quality of life,
therefore its dose-volume relationship has been investigated
in several trials (1, 2, 5-8, 12-14, 17-21). Results have
differed considerably across different institutions regarding
which dosimetric factors are more critical than others. Jim
Rose and colleagues performed a systematic literature review
of published studies addressing radiation oesophagitis after
thoracic radiotherapy in 2009 (18). Statistically significant
relationships between specific dose-volume parameters
[V20Gy, V35Gy, V60Gy, maximal and mean oesophageal dose]
with or without chemotherapy and clinically significant acute
oesophagitis risk were identified based on the analyzed
studies. They found various dosimetric correlations in the
literature on oesophageal toxicity regarding the seriousness
of the swallowing complaints. Identification of the risk
factors for acute oesophagitis in lung cancer is important for
optimizing the most effective and favourably-tolerated
treatment plan. Our aim was to prospectively investigate the
dosimetric correlations of acute oesophageal toxicity (AET)
during neoadjuvant and definitive paclitaxel-based three-
dimensional conformal CRT in patients with non-small cell
lung cancer. 
Patients and Methods
The study was conducted in full accordance with the institutional
regulations and all the patients gave their written informed consent
to participate in the chemotherapy and radiotherapy. 
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Study population. Patients receiving CRT for primary unresectable
or potentially operable non-small cell lung cancer at the Department
of Oncotherapy between December 2006 and June 2011 were
eligible for participation in this study. Histological examination was
performed before the therapy in all cases. Staging examinations
were based on conventional protocols [chest computed tomography
(CT), abdominal ultrasound/CT, brain CT, bone scan,
bronchoscopy]. For each patient the multimodal treatment strategy
was designed by a multidisciplinary team.
Chemo- and radiotherapy, supportive therapy. During the
radiotherapy all the patients received concomitant taxane-based
chemotherapy (weekly paclitaxel 100 mg/m2 in 4-6 cycles,
depending on toxicity). Out of the 40 patients (stage IIIB) who
completed induction chemotherapy (one or two cycles), 38 (95%)
received a taxane-based chemotherapy regimen (mainly paclitaxel
175 mg/m2, carboplatin 400 mg/m2 or docetaxel 75 mg/m2, cisplatin
75 mg/m2, at 3-week intervals), while two patients received a
gemcitabine-based regimen (gemcitabine 1250 mg/m2 on days 1 and
8, cisplatin 70 mg/m2 on day 1, and then at 3-week intervals) for at
least four weeks prior to the concomitant CRT. All patients were
irradiated in the supine position, with both arms elevated above the
head, on the thorax set of the AIO SolutionTM (ORFIT, Antwerpen
Belgium). CT-based three-dimensional treatment planning and
conformal radiotherapy were performed in all cases, with use of an
individual immobilization system with thermoplastic masks. The
gross tumor volume (GTV), macroscopic lung cancer, the involved
mediastinal and hilar lymph nodes were defined on [18F]fluoro-2-
deoxy-d-glucose positron emission tomography-CT images. The
delineation of organs at risk (spinal cord, ipsilateral and
contralateral lung, heart and oesophagus) was conducted according
to the local protocol. The planning target volume encompassed the
GTV, the involved lymph node regions (clinical target volume) and
the safety margins. The initial radiation dose was 25×1.8 Gy (and
the total dose for neoadjuvant cases); after a repeated CT scan,
depending on the tumour response, radiotherapy of the reduced
volume was then continued based on a new three-dimensional plan,
to an additional average dose of 22-26 Gy, resulting in a total dose
of 67-72 Gy. Avoiding smoking and consumption of hot and spicy
food, chopped food was recommended in order to prevent from
AET. Symptoms were alleviated based on protocols with local
anaesthetics, liquid, mushy food, antihistamines, when required with
mucosal coating, proton-pump inhibitors, tramadol derivatives,
systemic non-steroids, or calcium.
Evaluation of AET. The whole oesophagus was contoured from the
anular cartilage to the gastroesophageal junction prior to radiation
planning. The following dosimetric data were analysed in relation to
dysphagia: the maximal dose (Dmax), the mean dose (Dmean), the
length of the irradiated oesophagus with 50 Gy (L50Gy) and the
volume of the oesophagus irradiated with 35 Gy to 60 Gy (V35-60 Gy).
AET as dysphagia was evaluated prospectively based on Common
Terminology Criteria for Adverse Events, version 3.0 issued by the
National Cancer Institute (Table I) (22). The worst grade of toxicity
was taken into account. Follow-up visits with the evaluation of
swallowing complaints were performed weekly. Patients who smoked
during the CRT were defined as smokers.
Statistical analysis. All statistical analyses were carried out using
SPSS version 20.0 for Windows (SPSS Inc., Chicago, IL, USA).
The relations between AET, age, gender, smoking habits and the
dosimetric data were evaluated. Age, dose and volume were
assessed with t-test, gender and smoking habits were analysed with
chi-square test. The relationship between dose-volume parameters
and severity of AET was analysed with logistic regression. Receiver
operating characteristic (ROC) analysis was used to find the cut-off
point for V45Gy.
Results
Patients’ characteristics. Altogether, data from 50 patients
were analyzed. Thirty-two (64%) patients were men, 18
(36%) were women. The mean±SD age was 59.8±8
(range=39-78) years. Histological examination showed
squamous cell carcinoma and adenocarcinoma in 22 (44%)
and 28 (56%) patients, respectively. Four (8%) patients had
stage II/B and six (12%) patients had stage III/A carcinoma.
Forty (80%) participants had stage III/B carcinoma. These
stages were determined according to the sixth edition of the
TNM system. Twenty-nine (58%) patients were smokers and
21 (42%) were non-smokers. Twelve (24%) patients
underwent operation, in one case, despite remission only
exploration was performed due to inoperable conditions. 
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Table I. Common Terminology Criteria for Adverse Events, Version 3.0 Dysphagia: (difficulty of swallowing).
Grade 1 Symptomatic, able to eat regular diet
Grade 2 Symptomatic and altered eating/swallowing (e.g. altered dietary habits, oral supplements); i.v. fluids indicated <24 h
Grade 3 Symptomatic and severely altered eating/swallowing (e.g., inadequate oral caloric or fluid intake); 
i.v. fluids, tube feedings, or TPN indicated ≥24 h
Grade 4 Life-threatening consequences (e.g. obstruction, perforation)
Grade 5 Death
TPN: Total parenteral nutrition.
Table II. Radiation dose (Gy) to critical organs (except the oesophagus).
Spinal cord Mean±SD 12.1±4.5
Maximal±SD 36±6.7
Ipsilateral lung Mean±SD 26.6±7.8
V20Gy±SD (%) 54.1±13.5
Contralateral lung Mean±SD 10.6±3.6
V20Gy±SD (%) 14.3±9.1
Heart Mean±SD 12.5±4.6
V30Gy±SD (%) 12.1±3.8
Dose parameters. The mean dose to the planning target
volume was 60.7±9.8 Gy for the whole investigated
population, while it was 64.7±5.5 Gy in the definitively
treated patients with irresectable disease. The preoperative
dose given was 45.0 Gy in all 10 cases. Irradiation doses to
spinal cord, heart, ipsilateral and contralateral lung are shown
in table II. The Dmax to the oesophagus was 57±10.8 Gy, and
the Dmean was 24.9±9 Gy. The mean L50Gy was 6.99±6.7 cm. 
Toxicity. Among the 50 participants, oesophageal toxicity did
not develop in 17 (34%) cases, while side-effects were
registered in 66%. AET of grade 1 and grade 2 developed in
16 (32%) and 14 (28%) cases, respectively (Table III). Grade
3 toxicity occurred in three (6%) cases. Life-threatening,
grade 4 or 5 AETs were not seen. Temporary interruption
due to vomiting, fever, neutropenia and acute oesophagitis
was necessary in 18 (36%) patients. The mean duration of
the interruption was 9.0 days. Out of 18 patients, the reason
for interruption was oesophageal toxicity in 12 (24%) cases.
Complaints were treated with local anaesthetics in all cases
with dysphagia. Use of drinkable nutrients was also indicated
for all patients, while tramadol treatment was needed in eight
(16%) cases. No association was found between oesophageal
toxicity and gender (p=0.584), age (p=0.271) or smoking
habit (p=0.196) of the patients.
Correlations of the dose- and volume data with AET. The
maximum and mean dose to the oesophagus correlated well
with moderate and severe swallowing toxicity. The Dmax to
the esophagus in cases of grade 0-1 and grade 2-3 toxicity
was 56±11.45 and 64.07±5.55 Gy, respectively (p<0.001).
The average Dmean for the cases with AET of grade 0-1 and
grade 2-3 was 21.87±8.24 and 30.98±7.57 Gy, respectively
(p<0.001). The average mean dose to the oesophagus among
the three patients with grade 3 AET was 34.46±5.58 Gy. The
L50Gy was also related to the symptoms (p<0.001). In cases
of grade 0-1 and grade 2-3 AET, the L50Gy was 5.10±5.66
and 10.54±3.83 cm, respectively (p<0.001). D30% ±SD was
39.82±14.17 and 53.74±7.21 Gy in grade 0-1 and grade 2-3
esophagitis, respectively (p<0.001). The V35-60Gy in relation
to toxicity is shown in Table IV. Examining the relationship
between oesophageal toxicity and dose-volume parameters
with logistic regression, we found that V45Gy predicts most
reliably the development of grade 2 or higher AET (odds
ratio=1.089, 95%-confidence interval: 1.033-1.148,
p=0.001). A one percent increase of V45Gy elevates the risk
of grade 2 or higher AET by 8.9%. The risk of the
development of AET of grade 2-3 was the highest above a
cut-off value for V45Gy ≥32.5% according to ROC analysis.
Discussion
In our prospective study, the occurrence of AET during
paclitaxel-based CRT for patients with non-small cell lung
cancer was analyzed in relation to patient and dosimetric
parameters. Combination of radiotherapy with chemotherapy
is directed to improve local control and survival of patients
with lung cancer patients (9, 10). Several studies have shown
that compared to radiotherapy-alone, concurrent CRT appears
to lower oesophageal radiation tolerance (21). AET is often a
dose-limiting factor that influences the treatment efficacy (4).
In our study, dose reduction or permanent interruption of
therapy were not necessary due to oesophageal toxicity. No
association was found between oesophageal toxicity and
gender, age or smoking habit of the patients. Similarly to the
literature, mild, acute swallowing toxicity or its absence was
detected in most of our cases (grade 0-1 in 66%) (1, 5, 13,
19, 21). These mild side-effects were easily managed but
grade 2 or higher dysphagia causes clinically relevant
symptoms (22) and remarkably influences the patient’s
quality of life. The incidence of grade 2 or more severe
oesophagitis was slightly higher in our cohort than in Ozgen
et al.’s trial (19), but lower than that in the study of
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Table III. Incidence of acute oesophageal toxicity (AET).
Severity of AET n=50 Grade 0 Grade 1 Grade 2 Grade 3 Grade 4-5
Patients on (%) 17 (34%) 16 (32%) 14 (28%) 3 (6%) 0
Table IV. Dosimetric parameters of acute esophageal toxicity. Data are
means ±SD.
Grade 0-1 Grade 2-3 p-Value 
(t-test)
n 33 (66%) 17 (34%)
Dmax (Gy) 54.56±11.45 64.07±5.55 <0.001
Dmean (Gy) 21.87±8.24 30.98±7.57 <0.001
V35Gy (%) 34.87±17.71 49.23±11.55 0.004
V40Gy (%) 30.93±17.67 46.41±12.04 0.002
V45Gy (%) 20.15±18.71 43.23±12.20 <0.001
V50Gy (%) 15.90±18.06 37.88±11.45 <0.001
V55Gy (%) 13±15.85 29.29±16.36 0.001
V60Gy (%) 8.03±12.31 19.23±16.22 0.009
Length 50Gy (cm) 5.10±5.66 10.54±3.83 <0.001
Rodriguez et al. (1), in which patients with lung cancer were
treated with 3D-CRT technique. Definitive differences were
detected in the applied concomitant chemotherapeutic agents
between the present and the mentioned studies. None of their
results perceived life-threatening grade 4 or 5 AETs. The
incidence of AET and its dose volume relationship has been
investigated in several trials (1, 2, 5-8, 12-14, 17-21).
Although dose-volume parameters are commonly used to
analyze the risk of acute oesophagitis, there are large
differences in the results, and in which of these parameters
have the most dominant effect on the risk of AET due to the
different approaches for evaluation. We compared dosimetric
parameters of the group of patients with mild swallowing
toxicity, or absence of it (grade 0-1) to the group with
moderate or severe dysphagia (grade 2 or more). In
corcordance with numerous other studies, grade 2 or higher
AET strongly correlated with the mean and the maximal
dose, and the length and volume of the irradiated oesophagus
(1, 8, 13, 19, 20). Many researchers have found association
between AET and mean or maximal dose to the oesophagus.
In the study of Qiao et al., during concurrent platinum-based
chemotherapy, mean and maximal dose (above 60 Gy) to the
oesophagus were related to grade 3 or more oesophageal
toxicity (17). Singh et al. had similar results, and found the
mean and maximal dose (higher than 58 Gy) to be associated
with grade 3 or more severe AET (12). In the study of Ozgen
et al., the mean dose to the oesophagus of 28 Gy or more
correlated with grade 2 or worse toxicity (19). Other authors
evaluated the correlation between AET and Vdose, which
describes the percentage of the oesophagus receiving specific
dose (V20Gy, V30Gy, V40Gy, etc.). In Takeda et al.’s study, the
incidence of grade 1 AET increased if more than 30% (V35Gy
>30%) of the oesophageal volume received 35 Gy (21). By
Rodriguez et al., V50Gy >30% was the most statistically
significant factor associated with AET of grade 1 or more (1).
Belderbos and Bradley found a correlation between grade 2
or worse dysphagia and V100%20-60Gy, or V5-70Gy,
respectively (13, 20). From our results, the parameter which
mostly correlated with grade 2 or more swallowing toxicity
was a mean dose of 45 Gy to the oesophagus with 32.5% as
a cut-off value. A one-percent increase elevated the risk of
swallowing toxicity by 8.9%. L50Gy was also related to
symptoms. Association between length of irradiated
oesophagus with 40-50 Gy or more and AET were also
detected in relation to grade 2 or 3 or more swallowing
toxicity in the literature (5, 13). Elevated radiation dose and
combining radiotherapy with chemotherapy in the hope of
better survival may increase the incidence of oesophagitis.
Development of AET is the most important limiting factor in
the radiotherapy of chest tumours, therefore during treatment
planning, a significant aim is to reduce the oesophageal
irradiated volume and dose to protect patients from serious
events. Our results indicate that keeping oesophageal V45Gy
lower than 32.5% during paclitaxel-based CRT for non-small
cell lung carcinoma helps to avoid moderate and severe
swallowing toxicity in patients.
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